Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Amryt Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Amryt Pharma's CEO'su Joe Wiley, Jan2015 tarihinde atandı, in görev süresi 8.25 yıldır. in toplam yıllık tazminatı $ 1.72M olup, şirket hissesi ve opsiyonları dahil olmak üzere 43.4% maaş ve 56.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.1% ine doğrudan sahiptir ve bu hisseler $ 10.36M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 3.6 yıldır.

Anahtar bilgiler

Joe Wiley

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	43.4%
CEO görev süresi	8.3yrs
CEO sahipliği	1.1%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Oct 18

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Sep 16

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Sep 08

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Jul 14

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Feb 04

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Dec 23

Amryt Group's Lojuxta receives marketing approval in Brazil

Dec 09

CEO Tazminat Analizi

Joe Wiley'un ücretlendirmesi Amryt Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2022	n/a	n/a	-US$790k
Jun 30 2022	n/a	n/a	US$3m
Mar 31 2022	n/a	n/a	US$3m
Dec 31 2021	US$2m	US$747k	US$1m
Sep 30 2021	n/a	n/a	-US$88m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$92m
Dec 31 2020	US$2m	US$727k	-US$105m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$92m
Mar 31 2020	n/a	n/a	-US$87m
Dec 31 2019	US$1m	US$588k	-US$63m

Tazminat ve Piyasa: Joe 'nin toplam tazminatı ($USD 1.72M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 3.23M ).

Tazminat ve Kazançlar: Joe şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Joe Wiley (51 yo)

8.3yrs

Görev süresi

US$1,720,000

Tazminat

Dr. Joseph A. Wiley, also known as Joe, M.D. was the Founder of Amryt Pharma plc and serves as its Chief Executive Officer since 2015. He has been a Director at Amryt Pharma plc since April 19, 2016. Dr. W...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Wiley	CEO & Director	8.3yrs	US$1.72m	1.1% $ 10.4m
Rory Nealon	CFO, COO & Company Secretary	8.3yrs	US$939.00k	0.51% $ 4.8m
Elizabeth Jobes	Chief Compliance Officer	2.3yrs	Veri yok	Veri yok
John McEvoy	General Counsel	5.6yrs	Veri yok	Veri yok
Stephen Joyce	Head of Marketing & Head of APAC	4.3yrs	Veri yok	Veri yok
Julie Eastwood	Head of Human Resources	no data	Veri yok	Veri yok
Helen Phillips	Head of Medical Affairs	no data	Veri yok	Veri yok
Sheila Frame	President of Americas	2yrs	Veri yok	Veri yok
Tracy Cunningham	Chief Medical Officer	less than a year	Veri yok	Veri yok
Jordi Casals	President of EMEA Region	less than a year	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: AMYT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joseph Wiley	CEO & Director	7yrs	US$1.72m	1.1% $ 10.4m
Stephen Wills	Independent Non-Executive Director	3.6yrs	US$88.00k	0.023% $ 220.5k
Alain Munoz	Independent Non-Executive Director	3.6yrs	US$58.00k	0.0070% $ 66.1k
Patrick V. J. Vink	Independent Non-Executive Director	3.6yrs	US$60.00k	0.0078% $ 73.5k
Donald Stern	Independent Non-Executive Director	3.6yrs	US$80.00k	0% $ 0
Raymond Stafford	Independent Non-Executive Chairman of the Board	7yrs	US$88.00k	0.61% $ 5.8m
Roni Mamluk	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0
George Hampton	Independent Non-Executive Director	3.6yrs	US$65.00k	0.031% $ 294.0k
Raj Kannan	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0

3.6yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AMYT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Amryt Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Recent updates

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt gets British marketing approval & orphan drug designation for rare skin disease gel

Amryt Pharma plc Provides Earnings Guidance for the Full Year 2022

Amryt Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa(R) (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt Announces European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Amryt's Filsuvez gets approval in EU to treat rare skin disorder

Amryt Presents Data for Mycapssa (Oral Octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa(R) (oral octreotide) at ENDO 2022

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Amryt Pharma plc Announces New Patent for Mycapssa®

Amryt Pharma plc Reaffirms Revenue Guidance for Fiscal Year 2022

CHMP Adopts positive opinion for Filsuvez(R) for the treatment of Dystrophic and Junctional EB

Amryt Pharma plc to Report Q1, 2022 Results on May 04, 2022

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Amryt Announces Successful Bioavailability Study for Mycapssa® (Octreotide Capsules)

Amryt Receives Complete Response Letter from the U.S. Food and Drug Administration for Oleogel-S10 NDA

Amryt Announces Oleogel-S10 EMA Regulatory Update

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide)

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients

Amryt Pharma: Advancing Novel Treatments For Rare And Debilitating Conditions

Amryt Pharma plc Provides Update on Regulatory Review Process for Oleogel-S1

Amryt Announces the Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Amryt Pharma plc Revises Revenue Guidance for the Year 2021

Amryt Pharma plc Announces Earnings Guidance for the Fiscal Year 2021

Amryt Pharma plc completed the acquisition of Chiasma, Inc. from MPM Capital and others.

U.S. Food and Drug Administration Confirms Amryt’s New Drug Application for Oleogel-S10 Will Not Require an Advisory Committee Meeting

U.S. Food and Drug Administration Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

Amryt Pharma plc entered into an agreement to acquire Chiasma, Inc. from MPM Capital and others for approximately $290 million.

Chiasma surges on merger agreement with Amryt

Amryt and Medison Pharma Canada Sign Distribution Agreement for Myalepta (Metreleptin) in Canada

Amryt Pharma plc to Report Q4, 2020 Results on Mar 04, 2021

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

Amryt and Medison Pharma inks distribution deal for Juxtapid, Lojuxta and Myalept

Amryt Pharma plc Receives Reimbursement Approval from Nice for Myalepta in England and Wales

Amryt's AP103 an Orphan Drug in U.S. for skin blistering disorder

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (Lomitapide) in Saudi Arabia

Amryt Group Receives Marketing Authorisation Approval for Lojuxta in Brazil

Amryt Group's Lojuxta receives marketing approval in Brazil

Amryt Pharma plc Raises Sales Guidance for the Full Year 2020

Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® in Epidermolysis Bullosa

Amryt Signs Distribution Agreement with Swixx BioPharma AG

Amryt and Swixx Sign Distribution Deal for Lojuxta

Amryt Pharma plc to Report Q3, 2020 Results on Nov 05, 2020

Amryt Pharma Intends to Cancel the Admission of the Ordinary Shares to Trading on the Euronext Growth Market

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş